With recent Phase 3 vaccine trials indicating positive results, analyst Lim Say Boon of CGS-CIMB sees developed markets (DMs) and emerging markets (EMs) to be largely vaccinated by 2021 and 2022 respectively. This in addition to a Biden victory in the recent US Presidential Elections signal upsides for Asean and the Asia-Pacific markets going forward. 

Although the timing of the announcements was within previous market expectations, the very act – and the claimed high levels of effectiveness – gives the market more visibility on forward earnings. The announcement of such positive developments reduces the equities risk premium, and hence supports higher stock prices in general,” writes Lim on 19 November. Pfizer claims that its candidate has 90% effectiveness while Moderna claims its candidate has 94.5%. 

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

Subscribe

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook